Anthem Biosciences Reports Quarterly Performance Review for Quarter Ended June 30, 2026
Anthem Biosciences Limited has released its unaudited financial results for the quarter ended June 30, 2026, detailing performance across both standalone and consolidated entities. The Company's Board of Directors approved these financials, along with a Limited Review Report from Statutory Auditors.The company also disclosed that during the quarter, it allotted 1,670,909 fully paid up equity shares of Rs. 2 each under its "ESOP Scheme 2024."
Standalone Financial Performance
For the quarter ended June 30, 2026, Anthem Biosciences reported a Total Income of Rs. 4,124.42 million (Mn). The results stood in comparison to the previous quarters and the year end data:| Particulars | Quarter Ended 30/06/2026 (Rs in Mn) | Quarter Ended 31/03/2026 (Rs in Mn) | Quarter Ended 30/06/2025 (Rs in Mn) | Year End 31/03/2026 (Rs in Mn) |
|---|---|---|---|---|
| Revenue from operations | 3,838.42 | 5,825.01 | 5,380.11 | 20,893.12 |
| Other income | 286.00 | 606.25 | 277.28 | 1,820.75 |
| Total Income | 4,124.42 | 6,431.26 | 5,657.39 | 22,713.87 |
| Profit for the Period/Year | 1,020.09 | 2,116.65 | 1,483.40 | 6,705.64 |
Consolidated Financial Highlights
The consolidated results of Anthem Biosciences Limited for the quarter ended June 30, 2026, showed a Total Income of Rs. 4,431.07 Mn. The Group's overall performance against previous periods is presented below:| Particulars | Quarter Ended 30/06/2026 (Rs in Mn) | Quarter Ended 31/03/2026 (Rs in Mn) | Quarter Ended 30/06/2025 (Rs in Mn) | Year Ended 31/03/2026 (Rs in Mn) |
|---|---|---|---|---|
| Revenue from operations | 4,182.18 | 6,109.43 | 5,402.09 | 21,243.33 |
| Other income | 248.88 | 512.12 | 228.12 | 1,557.83 |
| Total income | 4,431.07 | 6,621.56 | 5,630.21 | 22,801.16 |
| Profit for the Period/Year | 1,199.41 | 1,897.58 | 1,357.91 | 5,917.92 |
Segmental Revenue Breakdown
The consolidated segment information provided details revenue and profit before tax across two key segments: CRDMO and Speciality Ingredients.| Segment Name | Q Ended 30/06/2026 (Revenue) | Q Ended 31/03/2026 (Revenue) | Q Ended 30/06/2025 (Revenue) | Year Ended 31/03/2026 (Revenue) |
|---|---|---|---|---|
| CRDMO Revenue | 3,408.02 | 5,128.36 | 4,527.11 | 17,727.68 |
| Speciality Ingredients Revenue | 774.16 | 981.07 | 874.98 | 3,515.65 |
| Total Segment Revenue | 4,182.18 | 6,109.43 | 5,402.09 | 21,243.33 |
The total profit before tax across the segments during the quarter ended June 30, 2026 was Rs. 1,445.81 million (Mn).
ANTHEM Stock Price Movement
Anthem Biosciences Limited shares settled in post-market trading today, successfully gaining 0.31% as it closed higher after a day of positive movement. The equity saw strong activity, with a total traded volume recorded at 648,680 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.